[1] Kamisawa T, Wood L D, Itoi T, et al. Pancreatic cancer[J]. Lancet, 2016,388(10039):73
[2] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA Cancer J Clin, 2018,68(1):7
[3] Garzon R, Calin G A, Croce C M. MicroRNAs in Cancer[J].Annu Rev Med, 2009,60(1):167
[4] Marchini S, Cavalieri D, Fruscio R, et al. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections[J]. Lancet Onco, 2011,12(3):273
[5] Fornari F, Milazzo M, Chieco P, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells[J]. Cancer Res, 2015,70(12):5184
[6] Duan Z, Choy E, Harmon D, et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration[J].Mol Cancer Ther, 2011,10(8):1337
[7] Wan D, He S, Xie B, et al. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers[J]. Med Oncol, 2013, 30(1):378
[8] Barrett T, Troup D B, Wilhite S E, et al. NCBI GEO: mining tens of millions of expression profiles—database and tools update[J]. Nucleic Acids Res, 2007,35(Database issue):760
[9] Lewis B P, Shih I H, Jones-Rhoades M W, et al. Prediction of Mammalian MicroRNA Targets[J]. Cell, 2003,115(7):787
[10] Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations[J]. Nucleic Acids Res, 2015, 43(D1):D146
[11] Paraskevopoulou M D, Georgakilas G, Kostoulas N, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows[J]. Nucleic Acids Res, 2013,41(Web Server issue):W169
[12] Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions[J]. Nat Methods, 2015,12(8):697
[13] Kertesz M, Iovino N, Unnerstall U, et al. The role of site accessibility in microRNA target recognition[J]. Nat Genet, 2007,39(10):1278
[14] Miranda K C, Huynh T, Tay Y, et al. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes[J]. Cell, 2006,126(6):1203
[15] Yousef M, Jung S, Kossenkov A V, et al. Na?觙ve Bayes for microRNA target predictions--machine learning for microRNA targets[J]. Bioinformatics, 2007,23(22):2987
[16] Huang D W, Sherman B T, Lempicki R A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nat Protoc, 2008,4(1):44
[17] Kinose Y, Sawada K, Nakamura K, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma[J]. Oncotarget, 2015,6(13):11342
[18] Huang J, Dong B, Zhang J, et al. miR-199a-3p inhibits hepatocyte growth factor/c-Met signaling in renal cancer carcinoma[J]. Tumor Biol, 2014,35(6):5833
[19] Han Y, Kuang Y, Xue X, et al. NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer[J]. Biomed Pharmacother, 2014,68(5):497
[20] Tian R, Xie X, Han J, et al. miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL[J]. Am J Cancer Res, 2014,4(6):738
[21] Koshizuka K, Hanazawa T, Kikkawa N, et al. Regulation of ITGA3 by the anti-tumor miR-199 family inhibits cancer cell migration and invasion in head and neck cancer[J]. Cancer Sci, 2017,108(8):1681
[22] Nagao Y, Hisaoka M, Matsuyama A, et al. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma[J]. Mod Patholo, 2012,25(1):112
[23] Bloomston M, Frankel W L, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis[J]. JAMA, 2007,297(17):1901
[24] 夏蜀珺, 郭俊超, 李建, 等. 胰腺癌早期诊断相关miRNAs的筛选与验证[J]. 中华外科杂志, 2014,52(3):198
[25] Kuninty P R, Linda B, Vegard T, et al. MicroRNA-199a and -214 as potential therapeutic targets in pancreatic stellate cells in pancreatic tumor[J]. Oncotarget, 2016,7(13):16396
[26] Wang X, He R, Zhao T, et al. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes[J]. Oncotarget, 2016,7(12):13717
[27] Eser S, Reiff N, Messer M, et al. Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer[J]. Cancer Cell, 2013,23(3):406
[28] Tong W G, Ding X Z, Talamonti M S, et al. LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways[J]. Biochem Biophys Res Commun, 2005,335(3):949
[29] Friess H, Yamanaka Y, Kobrin M S, et al. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression[J]. Clin Cancer Res, 1995,1(11):1413
[1]李辰运,孙 彤,卓 娜,等.胰腺导管腺癌中腺苷酸激酶4 的表达及临床意义[J].天津医科大学学报,2018,24(01):43.
LI Chen-yun,SUN Tong,ZHUO Na,et al.Expression of AK4 in pancreatic ductal carcinoma and its clinical significance[J].Journal of Tianjin Medical University,2018,24(02):43.
[2]王 艳,郭 志,杨雪玲,等.CT引导下125I粒子植入对缓解胰腺癌疼痛的疗效观察[J].天津医科大学学报,2019,25(02):132.
WANG Yan,GUO Zhi,YANG Xue-ling,et al.CT-guided iodine-125 seeds implantation therapy for pancreatic cancer patients with pain[J].Journal of Tianjin Medical University,2019,25(02):132.
[3]方闯,田伟军.TGF-β/SMAD4信号通路中基因突变对胰腺癌患者生存的影响[J].天津医科大学学报,2020,26(05):450.
FANG Chuang,TIAN Wei-jun.The effect of mutations in TGF-β/ SMAD4 signal pathway on the survival of patients with pancreatic cancer[J].Journal of Tianjin Medical University,2020,26(02):450.
[4]周 彤,赵 倩.整合多组学数据筛选胰腺癌进展中的关键基因[J].天津医科大学学报,2024,30(02):132.[doi:10.20135/j.issn.1006-8147.2024.02.0132]
ZHOU Tong,ZHAO Qian.Integrating multi-omics data to screen key genes in pancreatic cancer progression[J].Journal of Tianjin Medical University,2024,30(02):132.[doi:10.20135/j.issn.1006-8147.2024.02.0132]